Top Story

Daclatasvir with PEG-IFN a-2a/ribavirin reduced treatment time for HCV

January 30, 2015

In a phase 2b clinical trial, a regimen of daclatasvir combined with pegylated interferon alfa-2a and ribavirin was safe and generally well tolerated among patients with hepatitis C virus genotype 2 and 3 infections, as well as reduced the duration of treatment, according to study data.

Researchers randomly assigned 151 patients with HCV genotype 2 (n=71) or 3 (n=80) infection to 60 mg daclatasvir (Bristol-Myers Squibb) for 12 or 16 weeks or placebo for 24 weeks, both combined with PEG-IFN a-2a and ribavirin. Fifty patients were in the 12-week group, 50 were in the 16-week group and 51 received placebo. Treatment duration was extended to 24 weeks if patients did not achieve an early virologic response.

John Ward

CDC, Quest collaborate to better screen, treat and reduce hepatitis

January 28, 2015
Quest Diagnostics has entered into an agreement with the Centers for Disease Control to assist in identifying new trends in screening, diagnosing and treating multiple…

Victrelis expected to be discontinued by December

January 27, 2015
Merck expects to discontinue the manufacturing and distribution of its protease inhibitor Victrelis for the treatment of hepatitis C virus by December, according to a…
In the Journals

Various regimens effective in treating Chinese patients with HBV

January 27, 2015
In an open-label clinical trial, treatment-naive patients with hepatitis B virus infection showed similar sustained virologic response rates to four different treatment…
CME
j64a_activity

CRITICAL ISSUES IN HBV: Considerations in Optimizing HBV Treatment

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

Hepatitis B virus (HBV) infection is a global epidemic with a worldwide burden. Physicians must address the importance…
More »
Meeting News Coverage Video
thumbnail for video 3895262652001

Early liver transplantation could improve survival rates for patients with alcoholic hepatitis

November 17, 2014
BOSTON — Ibrahim A. Hanouneh, MD, hepatologist at Cleveland Clinic, discussed results of a study that compared…
More »
CME
HCV Consults: Volume 1, Number 2

HCV Consults: Volume 1, Number 2

This activity is supported by educational grants from AbbVie and Genentech.

Approved interferon-free therapy has already become entrenched among clinicians for patients with HCV genotypes 2 and…
More »
In the Journals

Daclatasvir with PEG-IFN a-2a/ribavirin reduced treatment time for HCV

January 30, 2015
In a phase 2b clinical trial, a regimen of daclatasvir combined with pegylated interferon alfa-2a and ribavirin was safe and generally well tolerated…
John Ward

CDC, Quest collaborate to better screen, treat and reduce hepatitis

January 28, 2015
Quest Diagnostics has entered into an agreement with the Centers for Disease Control to assist in identifying new trends in screening, diagnosing and…

Victrelis expected to be discontinued by December

January 27, 2015
Merck expects to discontinue the manufacturing and distribution of its protease inhibitor Victrelis for the treatment of hepatitis C virus by…
In the Journals

Various regimens effective in treating Chinese patients with HBV

January 27, 2015
In an open-label clinical trial, treatment-naive patients with hepatitis B virus infection showed similar sustained virologic response rates to four…
In the Journals

Tenofovir showed better efficacy, safety than adefovir dipivoxil in Chinese patients with HBV

January 23, 2015
In a Chinese cohort of patients with hepatitis B virus infection, therapy with tenofovir disoproxil fumarate was safe and effective in treating the…

Prime Therapeutics to supply both Harvoni and Viekira Pak for HCV

January 22, 2015
Prime Therapeutics LLC has entered into agreements with Gilead Sciences for the sale of Harvoni, and with AbbVie for the sale of Viekira Pak. The…
In the Journals

HCV mortality rates stabilized or increased across three regions

January 21, 2015
Liver-related mortality rates after hepatitis C virus infection diagnosis were either stabilized or increased during a period of time in Scotland…
In the Journals

Anti-viral regimens did not increase risk for renal effects in HBV

January 20, 2015
Anti-viral therapy did not increase any risk for renal disease among patients with hepatitis B virus infection, with or without renal risk factors…

Newly approved HCV treatment regimen available in the UK

January 19, 2015
Following a European Marketing Authorization last week, Viekirax plus Exviera, with or without ribavirin, is now available in the United Kingdom for…

HCV treatment regimen approved by European Commission

January 16, 2015
The European Commission granted marketing authorizations for Viekirax plus Exviera, with or without ribavirin, for the treatment of chronic hepatitis…
More Headlines »
morganatic-roan
morganatic-roan